CSafe , a provider of active and passive temperature-controlled shipping solutions for the biopharmaceutical industry, proudly announces the launch of a new line of multi-purpose cryogenic dewars for the cell and gene therapy market. The progressive technology, which is the first in CSafe’s CGT Cryo series, maintains temperatures below -150°C.
Reusable Dewars and high-impact shipping boxes are designed to safely transport critical cell and gene therapies, including pre-frozen biologics, regenerative medicine, immunotherapies, stem cells, and CAR-T cells.
“The cell and gene therapy industry needs more solutions that integrate data with products, along with a global network with advanced capabilities and service infrastructure,” said Patrick Schafer , CEO of CSafe. “Our team has worked tirelessly to develop these new solutions to ensure the integrity of our customers’ valuable cargo and ultimately provide peace of mind.”
These cutting-edge solutions offer a host of key features designed to meet stringent industry standards. Preconditioned using liquid nitrogen, these dry vapor units boast an impressive retention time of over 10 days against the ISTA 7D thermal profile, providing high levels of reliability for critical shipments. They include integrated TracSafe RLT real-time data tracking devices to monitor internal product temperature, external ambient temperature, shock, tilt and location throughout the shipping journey. Through CSafe Connect, the company’s digital portal, customers can easily track their order, access real-time data and upgrade to the premium Control Tower shipping monitoring service for greater tracking and control.
Additionally, multi-purpose dewars provide additional protection with security seals and a lockable shipping case to prevent tampering during transit. The dry steam unit complies with IATA Dangerous Goods Regulations and the domed shipping box lid prevents stacking to ensure stable, upright orientation during transit and handling. Qualified to industry standards, including ISTA 3A for distribution and ISTA 7D for thermal qualification, these high-performance solutions offer customers peace of mind.
“Our new line from Dewars is not just a product, it is a promise,” said Emilio Frattaruolo , vice president of cell and gene therapies. “A promise of precision and reliability as we venture into the next frontier of innovation in cell and gene therapies.”
SOURCE: PRNewswire